Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Pregnancy-related contraception and the general concept of potential fetal harm are partially supported, but multiple specific pregnancy risk assertions (e.g., heart defects, cleft palate, trimester-specific miscarriage, preterm labor, low birth weight), plus monitoring and alternative-therapy recommendations, are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Lurbinectedin is administered intravenously.
Supported that lurbinectedin is administered intravenously (referenced in provided excerpts under 8.1 Pregnancy and 5.5 Embryo-Fetal Toxicity: “Intravenous administration of a single lurbinectedin dose …”).
Effective birth control should be used to prevent unintended pregnancy while taking lurbinectedin.
Supported (8.3: effective contraception during treatment and post-treatment; and 8.3: verify pregnancy status).
The use of lurbinectedin during pregnancy is not well established.
Partially supported (8.1 Pregnancy: “There are no available data to inform the risk of ZEPZELCA use in pregnant women.”).
Unsupported Statements
Lurbinectedin is a chemotherapy medication used to treat certain types of cancer, including small cell lung cancer.
No supporting content in the provided label excerpts for indications or small cell lung cancer.
Lurbinectedin is used to treat relapsed or refractory ovarian cancer.
No supporting content in the provided label excerpts for this indication.
Lurbinectedin inhibits the growth of cancer cells.
No supporting statement in the provided label excerpts.
Lurbinectedin is typically used in combination with other chemotherapy medications.
No combination-therapy statement is provided in the available excerpts.
Lurbinectedin may increase the risk of birth defects, including heart defects.
Provided pregnancy excerpt discusses fetal harm/embryolethality and does not specify heart defects.
Lurbinectedin may increase the risk of birth defects, including cleft palate.
Provided pregnancy excerpt does not specify cleft palate.
The risk of miscarriage with lurbinectedin is particularly higher if taken during the first trimester of pregnancy.
No trimester-specific miscarriage risk is described in the provided excerpts.
Lurbinectedin may increase the risk of preterm labor.
Preterm labor risk is not mentioned in the provided pregnancy excerpt.
Lurbinectedin may increase the risk of low birth weight.
Low birth weight risk is not mentioned in the provided pregnancy excerpt.
Pregnant women taking lurbinectedin should be aware of potential risks including birth defects, miscarriage, preterm labor, and low birth weight.
The provided excerpt supports potential fetal harm and includes background major birth defects and miscarriage, but does not mention preterm labor or low birth weight.
It is possible to become pregnant while taking lurbinectedin.
No statement in the provided excerpts addresses the possibility of pregnancy while taking lurbinectedin.
If pregnancy occurs while taking lurbinectedin, the healthcare provider will closely monitor the pregnancy to detect potential problems early.
No monitoring instruction such as “closely monitor” is present in the provided excerpts.
If pregnant or planning to become pregnant, healthcare providers may recommend alternative treatments that are safer during pregnancy.
The provided excerpts advise risk/contraception but do not mention alternative therapies.
Contradictions
Important Omissions
Any boxed warning/contraindication information was not evaluable because no corresponding label sections were provided.
Importance:
Moderate
No dosage and administration details beyond IV route were assessed because the label section 2 content was not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several pregnancy-risk claims add specific fetal outcomes (e.g., heart defects, cleft palate), trimester-specific miscarriage risk, and additional outcomes (preterm labor, low birth weight) that are not supported by the provided label excerpts; additionally, specific monitoring and alternative-therapy guidance is introduced without label support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Over-specific and unsupported embryo-fetal risk details and additional pregnancy outcomes (heart defects, cleft palate, trimester-specific miscarriage, preterm labor, low birth weight), plus unsupported pregnancy-management language and alternative-treatment speculation.
Suggested Improvement
Limit pregnancy counseling to statements supported by the provided label excerpts: no available human pregnancy risk data, potential fetal harm/embryolethality based on animal data, advise pregnant women/females of reproductive potential of potential risk, and advise effective contraception timing (7 months for females; 4 months for males). Remove unsupported specific defect types, trimester-specific claims, and outcomes not mentioned (preterm labor, low birth weight), and avoid “closely monitor”/alternative-therapy recommendations unless present in the label.